Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Cardiovascular Risks of Fingolimod in MS
NCT02232061Phase 4Completed
- Sponsor
- Novartis
- Start
- Sep 2014
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 4 trial of fingolimod in multiple sclerosis (MS), sponsored by Novartis. Started Sep 2014; status: completed.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02232061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02232061.